Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA-HBs
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DNA-HBs (also referred to as DNA.HBs or pSG2.HBs) is an investigational plasmid DNA therapeutic vaccine developed by the University of Oxford's Centre for Clinical Vaccinology and Tropical Medicine in collaboration with the Medical Research Council Laboratories in The Gambia. It is designed to treat chronic hepatitis B virus (HBV) infection by encoding the hepatitis B surface antigen (HBsAg). The vaccine aims to stimulate both cell-mediated and humoral immune responses to help clear the virus in chronically infected individuals. In clinical trials, it has been evaluated as part of a heterologous prime-boost regimen, typically serving as the priming agent followed by a boost with MVA.HBs (a recombinant modified vaccinia virus Ankara). These studies have also explored the vaccine's efficacy when used in combination with the antiviral drug lamivudine (3TC) in both HBeAg-negative and HBeAg-positive participants.
- Other names
- pSG2.HBspSG-2.HBspSG 2.HBs
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on DNA-HBs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA-HBs.